中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Pipeline
Pipeline
Clinical Trials
Partnership
Investors
Financials & Filing
Upcoming Events
Corporate presentation
SCIENTIFIC PRESENTATIONS
News
Careers
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Show More
2015
2014
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
2026-01-05
浙公网安备 33010802003344号
浙ICP备11050387号-1